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Yun-Yan Xiang1,2†, Haiheng Dong3†, Burton B Yang4, John F MacDonald1,2 and Wei-Yang Lu1,2,3,5*Abstract
Background: Excess expression of acetylcholinesterase (AChE) in the cortex and hippocampus causes a decrease in
the number of glutamatergic synapses and alters the expression of neurexin and neuroligin, trans-synaptic proteins
that control synaptic stability. The molecular sequence and three-dimensional structure of AChE are homologous to
the corresponding aspects of the ectodomain of neuroligin. This study investigated whether excess AChE interacts
physically with neurexin to destabilize glutamatergic synapses.
Results: The results showed that AChE clusters colocalized with neurexin assemblies in the neurites of hippocampal
neurons and that AChE co-immunoprecipitated with neurexin from the lysate of these neurons. Moreover, when
expressed in human embryonic kidney 293 cells, N-glycosylated AChE co-immunoprecipitated with non-O–glycosylated
neurexin-1β, with N-glycosylation of the AChE being required for this co-precipitation to occur. Increasing extracellular
AChE decreased the association of neurexin with neuroligin and inhibited neuroligin-induced synaptogenesis. The
number and activity of excitatory synapses in cultured hippocampal neurons were reduced by extracellular catalytically
inactive AChE.
Conclusions: Excessive glycosylated AChE could competitively disrupt a subset of the neurexin–neuroligin junctions
consequently impairing the integrity of glutamatergic synapses. This might serve a molecular mechanism of excessive
AChE induced neurodegeneration.
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As the key enzyme that hydrolyzes acetylcholine, acetyl-
cholinesterase (AChE) plays a critical role in regulating
cholinergic signaling. Neurons in the central nervous
system generate two isoforms of AChE: synaptic AChE
(AChE-S, also known as “tailed AChE”) and read-through
AChE (AChE-R). In adults, AChE-S is the predominant
isoform, although AChE-R increases following exposure
to a variety of stressors [1]. In the extracellular space,
AChE exists in both soluble and membrane-bound forms.
Soluble AChE includes monomeric AChE-R, as well as* Correspondence: wlu53@uwo.ca
†Equal contributors
1Robarts Research Institute, University of Western Ontario, London, Ontario,
Canada
2Department of Physiology and Pharmacology, University of Western
Ontario, London, Ontario, Canada
Full list of author information is available at the end of the article
© 2014 Xiang et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.globular monomers and dimers of AChE-S. Membrane-
bound AChE consists of AChE-S tetramers tethered to the
cell membrane by a proline-rich membrane anchor [2].
Interestingly, membrane-bound AChE-S can be released
in response to cholinergic activation [3]. Collective data
imply that the isoforms, concentrations and localization of
AChE within the brain are dynamically regulated.
In the brain, AChE is produced by cholinergic neurons
[4], cholinoceptive neurons [5], and astrocytes [6]. Clinical
studies have indicated that an increase in anomalous
AChE is strongly correlated with the pathogenesis of
Alzheimer disease (AD) [7-10]. Specifically, AChE is a
major component of amyloid-β (Aβ) plaques [11], and
N-glycosylated AChE is increased in the cerebrospinal
fluid of patients with AD [12]. In particular, AChE binds
to Aβ, thus promoting both the formation of Aβ fibrils
[13] and the occurrence of neurotoxicity [14]. Moreover,
augmenting AChE expression in the brains of transgenictd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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formation [15]. However, the molecular mechanism or
mechanisms by which anomalous AChE contributes to
the pathogenesis of AD remain uncertain.
A progressive loss of synapses in the cortex and hippo-
campus is characteristic of early-stage AD [16]. Synaptic
development and stability are regulated by the interaction
of neurexin and neuroligin, transmembrane proteins that
are expressed in the pre- and post-synaptic membrane do-
mains of neurons, respectively [17,18]. These two proteins
connect via their ectodomains to form a trans-synaptic
junction. Neurexin and neuroligin also interact, via their
cytoplasmic tails, with the PDZ domains of specific scaf-
folding proteins in the pre- and post-synaptic compart-
ments, respectively. In this way, the neuroligin–neurexin
junctions promote trans-synaptic adhesion and assist in
the assembly of pre- and post-synaptic specializations
[19]. Interestingly, the molecular sequence and three-
dimensional structure of the ectodomain of neuroligins
are homologous to the corresponding aspects of AChE
[20]. We previously showed that over-expression of AChE
alters the expression of neurexins and neuroligins and
decreases the number of glutamatergic synapses in hippo-
campal neurons [21]. The objective of the present study
was to determine if increased expression of AChE leads
to a decrease in the neurexin–neuroligin junctions and
consequently to a reduction in glutamatergic synapses.
Results
Interaction between AChE and neurexins in
Hippocampal neurons
We first investigated whether AChE interacts physically
with neurexins. Specifically, we performed immunostaining
for extracellular AChE in living neurons, followed by coun-
terstaining for neurons under membrane-permeabilized
conditions. Consistent with the results of an earlier study
[22], we found that membrane-bound extracellular AChE
molecules assembled in small bunches along neurites
and were also found in larger patches associated with
the perikaryon (Figure 1A-1, middle panels). In contrast,
as previously reported [23], neurexin immunoreactivity
was diffusely distributed in the perikarya, with small
clusters in some neurites (Figure 1A-1, left panels). AChE
immunoreactive particles were co-localized primarily with
immunofluorescent clusters of neurexin (Figure 1A-1,
right panels). Treating neurons with the AChE inhibitor
BW284c51 decreased the fluorescent intensity of dispersed
neurexins in most subcellular compartments but increased
the fluorescent intensity of neurexin clusters in neurites
(Figure 1A-1, left panel, inset). Inhibition of AChE activity
increases the expression of AChE [24]. Indeed, treating
the neurons with BW284c51 significantly increased the
size of AChE particles (Figure 1A-1, middle panels, and
Figure 1A-2a) and increased co-localization fraction ofAChE with neurexin clusters (Figure 1A-1, right panels,
and Figure 1A-2b). Immunoblotting assays (Figure 1B-1)
confirmed that BW284c51 treatment increased AChE
expression but decreased neurexin expression in neurons
(Figure 1B-2).
We then conducted reciprocal immunoprecipitation of
neurexin and AChE from lysates of cultured hippocampal
neurons. These assays demonstrated that immunopre-
cipitation of AChE using an AChE antibody led to co-
precipitation of neurexin proteins which exhibited two
bands; and BW284c51 treatment increased this co-
precipitation (Figure 1C). In turn, a neurexin antibody,
but not IgG protein, co-precipitated a single AChE band
at about 68 kDa (Figure 1D). These results implied that
AChE molecules are able to interact with some neurexin
molecules in primary hippocampal neurons.
Regulation of AChE–neurexin interaction by
protein glycosylation
Mammalian neurons express both AChE-R and AChE-S,
with each isoform displaying distinctive properties in
molecular assemblies [25]. To study which AChE iso-
form interacts with neurexin-1β, we expressed Nrxn-
1β-1’-His with either hAChE-S or hAChE-R in HEK293
cells. We began with outlining the expression profiles
of these proteins in the transfected cells.
Consistent with the results of a previous study [26],
immunoblotting the lysates of hAChE-S transfected cells,
using anti-AChE, revealed a dense band at molecular
weight about 136 kDa (Figure 2A, right lane), as well as
two lighter bands at molecular weights about 66 and
68 kDa, respectively (see illustrations in Figure 2A’).
The 66- and 68-kDa bands correspond to monomers of
AChE-S [27-29], whereas the 136-kDa band may represent
dimers of AChE-S. Blotting the lysates of hAChE-R
transfected cells with anti-AChE also revealed two pro-
tein bands at molecular weights about 68 and 70 kDa
(Figure 2A, middle lane; also see Figure 2A’), both of which
should be globular monomers, as hAChE-R lacks the
domain for polymerization. In addition, immunoblotting
assays revealed that the hAChE-S and hAChE-R proteins
had very similar profiles in the culture medium of trans-
fected HEK293 cells (Figure 2B). Ellman esterase assays
revealed that under our experimental conditions, the
activity of hAChE in the culture media was about 1.0–1.5
units/ml for hAChE-S and 2.0 units/ml for hAChE-R.
To study the glycosylation pattern of AChE in mam-
malian cells, lysate of HEK293 cells transfected with
AChE-R was treated with N- or O-glycohydrolases, both
separately and in combination (Figure 2C). In another
set of experiments, HEK293 cells transfected with AChE-S
were treated with the N-glycosylase inhibitor tunicamycin
(Figure 2D). Notably, immunoblotting of AChE-R from the
cell lysate treated with the N-glycohydrolase PNGase F
Figure 1 Membrane-bound extracellular molecules of acetylcholinesterase (AChE) are clustered and co-localized with clustered neurexins
in primary neurons. A-1. Confocal microscopic images illustrating the intracellular localization of immunofluorescence of neurexins (Nrxn, left column)
and membrane-bound extracellular AChE (middle column) in cultured hippocampal neurons under control conditions (top panel) and in neurons
treated with the AChE inhibitor BW284c51 (lower panel). The right column illustrates the immunofluorescence overlay of the two proteins. Insets under
each panel illustrate the subcellular distribution of the two proteins. Note co-localization of neurexin and AChE immunofluorescent clusters in neurites.
A-2a. Total area (pixels) of AChE-immunoreactive clusters in control and BW284c51-treated neurons (control: 356 ± 100, n = 10 image fields; BW284c51:
682 ± 78, n = 10 image fields; P < 0.05). A-2b. Fraction of colocalization of AChE clusters with Nrxn clusters (control: 0.6 ± 0.08, n = 12 image fields;
BW284c51: 0.82 ± 0.07, n = 12 image fields; P < 0.05). B-1. Immunoblots showing increase of AChE and decrease of neurexin in BW284c51-treated
neurons. B-2. BW284c51treatment increased the total quantity of AChE (140%± 11% of control) but decreased the total amount of neurexin (59% ±
10% of control). C. Co-immunoprecipitation assay of lysates of control neurons and neurons treated with BW284c51. The immunoprecipitating AChE
co-precipitates with neurexin (Nrxn, middle lane), and BW284c51 enhances this co-precipitation (right lane). D. Assay for co-immunoprecipitating AChE
using a neurexin antibody from lysates of control neurons under various control conditions. From left to right, lane 1: control neuron lysate without
anti-neurexin antibody (anti-Nrxn); lane 2: control neuron lysate with IgG; lane 3: control neuron lysate with anti-neurexin; lane 4: BW284c51-treated
neuron lysate with anti-neurexin. Note co-precipitation of AChE in lane 3 and increase in co-precipitation of AChE in BW284c51-treated neurons.
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treated with tunicamycin (Figure 2D) disclosed a single
protein band, representing non-glycosylated AChE mono-
mers. Specifically, the molecular weight of non-glycosylated
AChE-R was about 64 kDa (Figure 2C), whereas the
molecular weight of non-glycosylated AChE-S was about
62 kDa (Figure 2D). In contrast, immunoblotting AChE
from the cell lysates treated with the O-linked glycohydro-
lases O-glycosidase and sialidase, separately or in combin-
ation, revealed two protein bands with the same molecular
weights as the control (Figure 2C). These results confirm
the previously reported finding that AChE molecules arehighly modified by N-glycosylation [26,30,31], but not by
O-glycosylation.
By immunoblotting His, four major bands of neurexin-
1β-1’, with molecular weights of about 55, 58, 73 and
91 kDa, respectively, were identified in total cell lysates
(Figure 3A) and in the membrane fraction (Figure 3B) of
HEK293 cells transfected with neurexin-1β-1’ alone or
with AChE-S. Notably, in the cell lysate the 91-kDa band
was faint whereas the 73-kDa band was dense (Figure 3A).
In the membrane fraction, both the 91- and 73-kDa bands
were strong, whereas the 55- and 58-kDa bands were
less intense (Figure 3B). Interestingly, co-expression of
Figure 2 Expression profile and glycosylation pattern of human acetylcholinesterase (hAChE) in human embryonic kidney 293 (HEK293)
cells. Expression profiles of read-through AChE (AChE-R) and synaptic AChE (AChE-S) in the cell lysate (A) and culture medium (B) of HEK293 cells
transfected with hAChE-R or with hAChE-S. The AChE-S proteins display a band with molecular weight of approximately132 kDa, and another two
bands with molecular weight of about 68 and 66 kDa, respectively, whereas the AChE-R proteins display two bands with molecular weight
of about 70 and 68 kDa, respectively. A’ illustrates the two lower molecular weight bands of AChE-S and AChE-R. C. Immunoblots of AChE-R
generated by processing the cell lysates with various N- and O-glycohydrolases (N = peptide N-glycosidase F, an N-linked glycohydrolase;
O = O-glycosidase and S = sialidase, two O-linked glycohydrolases). D. Immunoblots of AChE-S generated by processing lysates of transfected
HEK293 cells without additional treatment (vehicle control [ctrl]) or with tunicamycin treatment (Tunic.).
Xiang et al. Molecular Brain 2014, 7:15 Page 4 of 17
http://www.molecularbrain.com/content/7/1/15AChE and neurexin-1β cDNA reduced the expression
of neurexin-1β (Figures 3A and 3B, right lane) but did
not affect the level of expression of AChE (not shown).
These results are in accord with previous in vivo findings
that over-expression of AChE decreases the expression of
neurexin [32].
We also studied the glycosylation pattern of neurexin-1β
in HEK293 cells. Our immunoblotting assays showed that
in the total cell lysates treated with the O-glycohydrolases
O-glycosidase and sialidase, the 73-kDa band of neurexin-
1β disappeared while the density of the 58-kDa band of
neurexin-1β increased dramatically (Figure 3C, left panel).
These results indicate that the 73 kDa neurexin-1β band
represents O-glycosylated forms. Notably, treating the
transfected cells with tunicamycin (Figure 3C, right
panel) and treating the lysates of transfected cells with
PNGase F (Figure 3C, left panel) caused a slight reduc-
tion in the molecular weight of all neurexin-1β protein
bands, from 55, 58 and 73 kDa, respectively, to about
53, 56 and 71 kDa, respectively. These results imply that
short sugar chains are linked to O-glycosylated forms of
neurexin-1β proteins by N-glycosylation, with the 53-kDa
band representing the non-glycosylated form. Collectively,
our results confirm a previous finding that neurexin-1β
has minor N-glycosylation, and the various molecular
weights of neurexin-1β primarily reflect various degreesof O-glycosylation [33]. In addition, our assays indicate
that a large amount of neurexin-1β proteins located in
the cell membrane is O-glycosylated.
We then examined whether neurexin-1β could be co-
precipitated with AChE from lysates of HEK293 cells that
had been co-transfected with Nrxn-1β-1’-His and either
hAChE-S or hAChE-R. Immunoprecipitating either AChE-
S (Figure 4A, lane 3 in upper panel) or AChE-R (Figure 4B,
lane 3) led to co-precipitation of a large amount of 55-kDa
Nrxn-1β-1’ and a small amount of 58-kDa Nrxn-1β-1’,
but did not lead to co-precipitation of 73-kDa Nrxn-1β-1’
(Figures 4A and B). Conversely, immunoprecipitation
of Nrxn-1β-1’ using anti-His antibody led to consistent
co-precipitation of both 66- and 68-kDa monomers of
hAChE-S (Figure 4A, lane 3 in lower panel). In the
control experiment, neurexin-1β was not co-precipitated
when the anti-AChE antibody was replaced with IgG
(Figure 4C, lane 2). Remarkably, when the transfected cells
were cultured in the presence of tunicamycin, immuno-
precipitation of AChE did not lead to co-precipitation of
neurexin-1β (Figure 4C, lane 4). Together, these results in-
dicate that 1) both AChE-S and AChE-R can interact with
a subset of neurexin-1β proteins that retain only N-linked
short sugar chains and 2) N-glycosylation of AChE and
neurexin-1β is required for interaction between these two
molecules.
Figure 3 Expression profile and glycosylation pattern of neurexin-1β in human embryonic kidney 293 (HEK293) cells. A. Expression
profiles of neurexin-1β-1’ (Nrxn -1β-1’) in total cell lysate of HEK293 cells that had been transfected with neurexin-1β-1’-His or synaptic acetylcholinesterase
(AChE-S) or both. Neurexin-1β-1’ proteins were confirmed by anti-His. B. Expression profiles of neurexin-1β-1’ in the membrane fractions of HEK293 cells
that had been transfected with neurexin-1β-1’-His alone or AChE-S alone or both. In both A and B, blotting His revealed multiple bands of neurexin-1β-1’.
Notably, co-transfection with AChE decreased the expression of neurexin-1β in the HEK293 cells. C. Left panel: Immunoblots of neurexin-1β-1’ generated
by processing the cell lysates with various N- and O-glycohydrolases (N = peptide N-glycosidase F, an N-linked glycohydrolase; O =O-glycosidase and
S = sialidase, two O-linked glycohydrolases). Right panel: Immunoblots of neurexin-1β-1’ generated by processing lysates of transfected HEK293 cells
without additional treatment (vehicle control [ctrl]) or with tunicamycin treatment (Tunic.). Note the similar change in molecular weight of the
neurexin-1β-1’ bands following treatment with N-glycosidase F and tunicamycin.
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splicing and AChE ligand
Interaction of neurexins with neuroligins decreases when
the 30 amino acid insert SS4 is present in the laminin G
domain of β-neurexins [34]. To determine whether SS4
affects the interaction AChE with neurexin-1β, we co-
immunoprecipitated the lysates of two sets of HEK293
cells: one set of cells transfected with hAChE-S and
Nrxn-1β-1’-His (without SS4) and another set of cells
transfected with hAChE-S and Nrxn-1β-3’-His (with
SS4) using anti-AChE. Similar to the non-O-glycosylated
Nrxn-1β-1’ (Figure 4D, lanes 1 and 2), non-O-glycosylated
Nrxn-1β-3’ molecules were also co-precipitated by anti-
AChE, displaying as two bands at molecular weights of
about 57 and 60 kDa, respectively (Figure 4D, lanes 3
and 4). However, at the same quantity of cell lysate pro-
teins, the amount of co-precipitated Nrxn-1β-3’ (Figure 4D,
lane 3) was less than that of co-precipitated Nrxn-1β-1’
(Figure 4D, lane 1). This result implies that alternative
splicing of the SS4 in Nrxn-1β regulates the interaction
between AChE–neurexin to some extent.
Surface anionic residues expressed on the esterase side
of AChE allow this molecule to interact with various
proteins [35-38]. To study whether some AChE ligandsand/or inhibitors regulate interactions between AChE and
neurexin, we examined co-immunoprecipitates of lysates
of A549 cells transfected with hAChE-S combined with ei-
ther Nrxn-1β-1’-His or with Nrxn-1β-1’-His in the absence
or presence of the AChE inhibitor physostigmine (10 μM,
added to the culture medium). Interestingly, physostig-
mine enhanced co-precipitation of AChE-S with neurexin-
1β-1’ and with neurexin-1β-3’ (Figure 4D, lanes 2 and 4),
which suggests that the AChE ligand may structurally
regulate the interaction of AChE with neurexin.
AChE interacts only with neurexin-1β located in
cell membrane
To test our hypothesis that AChE interacts with the
ectodomain of β-neurexin, we transfected one set of
HEK293 cells with Nrxn-1β-1’-His and another set of
HEK293 cells with AChE-S. Sixteen hours after trans-
fection, we co-cultured the two sets of transfected cells
for another 24–32 hours in the absence or presence of
physostigmine. Immunoprecipitating the lysate of these
co-cultured cells with anti-AChE led to co-precipitation of
the 55-kDa Nrxn-1β-1’ protein, which was confirmed
by blotting His (Figure 4E, lane 2). Again, physostigmine
increased the band density of co-precipitated Nrxn-1β-1’
Figure 4 Co-immunoprecipitation of neurexin-1β with acetylcholinesterase (AChE). A. Representative blots of co-immunoprecipitation of
neurexin-1β with AChE from lysate of HEK293 cells transfected with neurexin-1β-1’-His (Nrxn-1β-1’, lacking alternatively spliced sequence 4 [SS4]) alone
or AChE-S alone or both. Upper panel: Immunoprecipitation of AChE-S from the lysate of HEK293 cells transfected with both neurexin-1β-1’-His and
AChE-S co-precipitated a large amount of 55-kDa neurexin-1β-1’ and a small amount of 58-kDa neurexin-1β-1’ but did not co-precipitate the
O-glycosylated 73- and 91-kDa forms. The co-precipitated neurexin-1β-1’ was confirmed by blotting His. Lower panel: Immunoprecipitation of
His co-precipitated AChE-S from the lysate of cells transfected with both neurexin-1β-1’-His and AChE-S. B. Immunoprecipitation of AChE-R
co-precipitated a large amount of 55-kDa neurexin-1β-1’ and a small amount of 58-kDa of neurexin-1β-1’ from the lysate of cells transfected
with both neurexin-1β-1’-His and AChE-R. C. In control experiments, absence of AChE antibody (lane 1) and application of IgG (lane 2) led to
absence of co-precipitation of neurexin-1β-1’. Similarly, when the transfected cells were cultured in the presence of tunicamycin (Tunic.), no
neurexin-1β-1’ was co-precipitated by anti-AChE (lane 4). D. Co-precipitation of neurexin-1β by anti-AChE from lysate of cells transfected with
AChE-S combined with neurexin-1β-1’ (from left to right: lanes 1 and 2) or combined with neurexin-1β-3’ (with SS4) (lanes 3 and 4). The transfected
cells were cultured in the absence (lanes 1 and 3) or presence (lanes 2 and 4) of 10 μM physostigmine (Physo.). Neurexin-1β was confirmed by blotting
His. The presence of physostigmine increased co-precipitation of neurexin-1β by anti-AChE, and the amount of co-precipitated neurexin-1β-3’ was less
than the amount of neurexin-1β-1’. E. Immunoprecipitation of AChE from the lysates of co-cultured HEK293 cells transfected with either Nrxn-1β-1’
or AChE-S before co-culturing. Anti-AChE co-precipitated the 55-kDa neurexin-1β-1’ from co-cultured the cells, and physostigmine increased
co-precipitation of neurexin-1β-1’.
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acts with the ectodomain of neurexin-1β. In another
experiment, we mixed the lysate of cells transfected with
AChE-S with the lysate of cells transfected with Nrxn-
1β-1’-His. In this test, anti-AChE did not co-precipitate
any Nrxn-1β-1’ from the cell lysate mixture, even in the
presence of physostigmine (not shown). Together, these
combined results suggest that AChE interacts only with
β-neurexins located on the cell membrane.
Excess AChE decreases the neurexin–neuroligin association
Excess AChE proteins binding to β-neurexins may reduce
the association of neurexin with neuroligin. To test this
possibility, we performed co-immunoprecipitation assays
of the lysate of HEK293 cells expressing Nrxn-1β-1’-His
and neuroligin-1. The cells were then cultured in medium
without (control) or with added AChE-S (1 unit/ml). As
expected, neuroligin-1 was co-immunoprecipitated withNrxn-1β-1’ (Figure 5A, lane 3, bottom panel). Culturing
the transfected cells in the presence of AChE-S signifi-
cantly reduced the amount of co-immunoprecipitated
neuroligin (Figure 5A, lane 4, bottom panel). This result
indicates that excess extracellular AChE indeed disrupts
the association of β-neurexins and neuroligin-1.
Next, we tested whether the disruption of the neurexin–
neuroligin association caused by excess AChE leads to
interruption of synaptic stability. Axonal terminals that
pass through non-neuronal cells transfected with neu-
roligin-1 initiate presynaptic differentiation, expressing
presynaptic proteins and forming presynaptic structures;
such synaptogenic activities are initiated by the interaction
between β-neurexin and neuroligin [39]. Using this cel-
lular model, we examined whether excess AChE in the
extracellular space could alter the neurexin-neuroligin
interaction induced presynaptic maturation. As previously
reported [39], we found that the axonal neurites of
Figure 5 Excess extracellular AChE decreases the association between neurexin and neuroligin and inhibits neuroligin-induced
presynaptic specialization. A. Cell lysates were prepared from HEK293 cells transfected with neurexin-1β-1’-His (Nrxn-1β-1’) alone (lane 1) or
neurogligin-1 (Nlgn-1) alone (lane 2) or both (lanes 3 and 4). Neurexin-1β-1’ was proved by blotting His (top panel), and neuroligin-1 was confirmed
by a neuroligin antibody (middle panel). Immunoprecipitation of His co-precipitated a heavy band of neuroligin from the lysate of cells expressing both
proteins (upper band in lane 3 of bottom panel). Immunoprecipitating His co-precipitated a smaller band of neuroligin from the lysate of cells cultured
in AChE-conditioned medium (upper band in lane 4 of bottom panel). B. Images of synapsin in primary neurons co-cultured with HEK293 cells
transfected with or without neuroligin-1. Left column, first row: HEK293 cells transfected with GFP alone; second row: Cells transfected with
GFP and neuroligin-1; third row: Cells transfected with GFP and neuroligin-1 and treated with AChE-conditioned medium. Middle column:
Axonal neurites of hippocampal neurons were identified by immunostaining of synapsin. No synapsin clusters were seen in axonal neurits
passing through GFP-expressing cells (Control; top row); whereas dense synapsin-clusters were formed on neuroligin-transfected cells (Nlgn;
middle row). Less synapsin-clusters were formed on neuroligin-transfected cells grown in AChE-conditioned medium (Nlgn + AChE; bottom
row). Right column; Overlay images of GFP-expressing cells and synapsin-positive structures. B’. Insets illustrate synapsin-clusters associated with control
cells (top), Nlgn-expressing cells (mid) and Nlgn-expressing cells in AChE-conditioned medium (bottom). C. Number of synapsin-positive clusters in
single cells transfected with vector (Ctrl, 0.8 ± 0.2, n = 36 cells), with neuroligin-1 (Nlgn, 22.5 ± 2, n = 19) or with neuroligin-1 and in AChE-conditioned
medium (Nlgn + AChE, 8.7 ± 1.3, n = 22, * P < 0.05, relative to conditions without AChE).
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immunoreactive presynaptic buttons on HEK293 cells
expressing neuroligin-1 (Figure 5B, middle row), and
such button-like presynaptic structures were not formed
by axonal neurites on control HEK293 cells (Figure 5B,
top row). This result confirms that neuroligin-1 does
indeed initiate development of presynaptic structures.
Importantly, we found that culturing the neuroligin-1-
expressing HEK293 cells in the AChE-S-conditioned
medium (with 5 μM physostigmine) greatly decreased the
number of synapsin-immunoreactive presynaptic buttons
on neuroligin-expressing cells (Figures 5B and C). Together,
these results imply that excess extracellular AChE could
inhibit synaptic development or interrupt synaptic stability,
by reducing the association of β-neurexin with neuroligin.
Excess AChE reduces glutamate-induced currents in
Hippocampal neurons
To examine whether increased expression of AChE im-
pairs synaptic function in neurons, we expressed hAChE-S
or hAChE-R in hippocampal neurons that had been
cultured in the medium containing 10 μM physostigmine.
Neurons expressing hAChE and GFP together or GFPalone (control) were identified by green fluorescence
(Figure 6A), and these GFP-expressing neurons accounted
for about 0.5%–1.5% of the total neuron population. Patch-
clamp recordings showed that the amplitude of glutamate-
induced currents in neurons expressing hAChE-S or
hAChE-R was significantly lower than the amplitude of
these currents in control neurons (Figures 6B and C).
In contrast, the amplitude of GABA-evoked currents in
AChE-expressing neurons was comparable to that of
GABA-evoked currents in control neurons (not shown).
We also measured glutamate currents in non-transfected
neurons closely surrounding the transfected neurons (with
cell-body-to-cell-body distance of 50–200 μm). Interest-
ingly, glutamate currents in these non-transfected neurons
were also lower than those of control neurons (Figure 6D).
These results indicate that increased expression of AChE
reduces glutamate receptor activity, likely through one or
more extracellular mechanisms. Indeed, adding 1.0–3.0
units/ml purified hAChE-S and 10 μM physostigmine
to the culture medium also decreased the glutamate
currents (Figure 6E). Furthermore, treating the neurons
with conditioned medium containing catalytically inactive
AChE-S (AChE-Sin) also substantially decreased glutamate
Figure 6 Increase in extracellular acetylcholinesterase (AChE) decreases glutamate-induced currents in primary neurons. A. Representative
images of cultured hippocampal neurons transfected with complementary DNA encoding AChE. Left panel shows cultured neurons under a light
microscope, and right panel displays a GFP fluorescent image of the same field. Red arrow indicates the cell body of a transfected cell. B. Traces of
glutamate-induced current in a control (Vector) neuron, a neuron expressing read-through AChE (AChE-R) and a neuron expressing synaptic AChE
(AChE-S). C. Amplitude of glutamate-induced current in control neurons (expressing GFP only), AChE-R-expressing and AChE-S-expressing neurons
(control: 1013 ± 181 pA, n = 11 neurons; AChE-R: 532 ± 69 pA, n = 11 neurons; AChE-S: 580 ± 72 pA, n = 12 neurons; * P < 0.05). D. Amplitude of
glutamate-induced current in control neurons and in neurons surrounding the AChE-R- and AChE-S-expressing neurons (control: 1881 ± 146 pA, n = 7
neurons; surrounding AChE-R-expressing neurons: 1157 ± 116 pA, n = 7 neurons; surrounding AChE-S-expressing neurons: 1236 ± 69 pA, n = 7 neurons;
* P < 0.05). E. Amplitude of glutamate-induced current in control neurons and in neurons treated with 3.0 units/ml human AChE-S (hAChE 3), 1.0 unit/ml
human AChE-S (hAChE 1) or 10 μM physostigmine (Physo) (control: 645 ± 68 pA, n = 11 neurons; hAChE 3: 413 ± 45 pA, n = 11 neurons; hAChE
1: 367 ± 90 pA, n = 9 neurons; Physo.: 587 ± 62 pA, n = 10 neurons; * P < 0.05). F. Amplitude of glutamate-induced current in control neurons
and in neurons treated with conditioned medium containing catalytically inactive AChE-S (AChE-Sin) (control: 2.6 ± 0.29 nA, n = 8 neurons;
AChE-Sin: 1.3 ± 0.22 nA, n = 11 neurons; * P < 0.05).
Xiang et al. Molecular Brain 2014, 7:15 Page 8 of 17
http://www.molecularbrain.com/content/7/1/15currents (Figure 6F). These results indicate that excess
extracellular AChE jeopardizes the glutamatergic function
of neurons through an extracellular mechanism that is
independent of its catalytic function.
Excess extracellular AChE decreases glutamatergic
synapses in primary neurons
We then examined whether excess extracellular AChE
impairs glutamatergic synapses in primary neurons. Spe-
cifically, we treated cultured hippocampal neurons at the
ninth DIV with AChE-S-conditioned medium and 10 μM
physostigmine. At the 12th DIV, we performed immu-
nostaining for synapsin and the GluR2 (GluA2) subunit
of glutamate receptors. These assays showed that the
increase in AChE-S was associated with significant re-
ductions in the number of synapsin clusters (Figures 7A
and B) and the expression of GluR2 (Figure 7C and 7D)
along dendritic neurites, indicating a reduction in the
number of glutamatergic synapses. To investigate the
effect of increased AChE on synaptic activity, we recorded
mEPSCs in cultured hippocampal neurons grown in
control medium (Figure 8A-1) or in AChE-S-conditioned
medium (Figure 8A-2). Increasing AChE in the culturemedium significantly reduced the frequency and ampli-
tude of the mEPSCs (Figures 8A-C).
Discussion
The activity and expression levels of AChE control the
amount of extracellular acetylcholine, which critically
regulates glutamatergic synaptic transmission. AChE has
non-catalytic functions in vitro [40,41] and in vivo [42],
some of which likely involve protein–protein interactions
[1]. Consistent with this notion, the present study revealed
that excess N-glycosylated AChE alters the structure and
function of glutamatergic synapses through its interaction
with non-O-glycosylated neurexins and a consequent
reduction in the association between neurexin and neuro-
ligin. These findings delineate a molecular mechanism
whereby excess glycosylated AChE could contribute to
neurological disorders in the brain. Previous studies have
shown that increased expression of AChE in cortical
neurons reduces the number of synapses and the levels
of β-neurexins both in vivo [43,44] and in vitro [21].
These results suggest crosstalk between AChE and neur-
exin. We hypothesized that these two proteins might
interact physically and anticipated that they would be
co-located in primary neurons. Indeed, our immunocyto-
Figure 7 Excess extracellular acetylcholinesterase (AChE) decreases glutamatergic synapses. A. Confocal microscopic images showing
immunofluorescent staining of synapsin in cultured hippocampal neurons at the 12th day in vitro (DIV). Panels show, from left to right, neurons in
control medium, in synaptic AChE (AChE-S)-conditioned medium containing 10 μM physostigmine (AChE + physo.) and in control medium containing
physostigmine (physo. 10 μM). White bar represents 20 μm. B. Numbers of synapsin-positive clusters per image field in neurons grown under various
conditions (control: 392 ± 26 clusters/field, n = 12 images; AChE + physo: 141 ± 33 clusters/field, n = 15 images; Physo. 381 ± 22 clusters/field, n = 9
images; * P< 0.05). C. Immunofluorescent staining of the GluR2 subunit of the glutamate receptor in cultured hippocampal neurons at the 12th DIV. Rows
represent neurons gown under various culture conditions: top row: control medium; middle row: AChE-conditioned medium+ 10 μM physostigmine;
bottom row: physostigmine alone. The GluR2 subunits on the membrane surface were stained first under non-permeabilizing conditions (red, middle
column) and the intracellular GluR2 subunits were then stained under permeabilizing conditions (green, left column). Right column shows overlay
images of surface and intracellular GluR2 subunits. C’. Enlarged images of the areas enclosed by a dotted line in C, illustrating GluR2 clusters in control and
AChE-treated neurons. Notably, increased extracellular AChE reduced the number of surface GluR2 subunit clusters but did not affect the immunoreactivity
of intracellular GluR2 subunits. D. Numbers of surface GluR2-positive clusters per image field in neurons cultured in various media (control: 440 ± 28
clusters/field, n = 8 images; AChE + physo.: 256 ± 50 clusters/field, n = 12 images; Physo.: 399 ± 48 clusters/field, n = 8 images; * P < 0.05).
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in neurites were co-localized with neurexin clusters
(Figure 1A-1), which implies a potential in situ associ-
ation between the two molecules. In addition, AChE
could be reciprocally co-precipitated with neurexin-1β
from the lysates of cultured neurons (Figure 1B, middle
lane). Furthermore, as previously reported [45], treating
neurons with the selective AChE inhibitor BW284c51 en-
hanced the expression of AChE (Figure 1B) and increased
the co-precipitation of AChE with neurexin (Figure 1C,
right lane). Together, these results imply that interactions
of AChE with neurexin occur in primary neurons.
The interaction between AChE and neurexin was fur-
ther substantiated by assaying lysates of HEK293 cells that
had been transfected with hAChE-R or AChE-S, either
separately or in combination with Nrxn-1β-1’ or with
Nrxn-1β-3’. Under natural conditions, AChE-R formed
only monomers, whereas AChE-S existed as monomers
and possibly dimers (Figures2A and 2B). As previouslyreported [26], under denaturing conditions (i.e., in the
presence of N-glycohydrolase), both isoforms of AChE
appeared as glycosylated monomers with reduced mole-
cular weight (Figure 2C). Under denaturing conditions,
neurexin-1β in cell lysates and membrane fractions also
exhibited glycosylated forms (Figures 3A and B). Specific-
ally, a large amount of neurexin-1β proteins in HEK293
cells had large molecular weights (73 kDa) as they were
associated with both N- and O-linked glycans, while a
lesser quantity of neurexin-1β exhibited smaller mo-
lecular weights (55 and 58 kDa) because they had only
N-glycosylation.
Remarkably, monomers of both AChE-S and AChE-R
were reciprocally co-immunoprecipitated only with the
N-glycosylated (55 and 58 kDa) neurexin-1β proteins,
not with the O-glycosylated (73 kDa) forms (Figures 4A
and B). These results are in accord with those of an earlier
study in which no interaction of AChE with the 72-kDa
neurexin-1β was detected [46]. However, our observation
Figure 8 Excess extracellular acetylcholinesterase (AChE) decreases glutamatergic synaptic activities. A. Representative traces of miniature
excitatory postsynaptic currents (mEPSCs) recorded at the 11th day in vitro in neurons grown in control medium (A-1) and in synaptic AChE
(AChE-S)-conditioned medium with 10 μM physostigmine (A-2). B. Cumulative distribution of the amplitude (B-1) and interval (B-2) of mEPSCs recorded
in a neuron cultured in control medium (Ctrl) and in a neuron grown in AChE-S-conditioned medium with physostigmine (AChE). C. Amplitude (C-1) and
frequency (C-2) of mEPSCs recorded in a group of neurons cultured in control medium (Ctrl) and in neurons grown in AChE-S-conditioned medium
with physostigmine (AChE). Amplitude under control conditions: 25.5 ± 2.5 pA, n = 6 cells; amplitude under high-AChE conditions: 20 ± 2 pA, n = 8 cells;
frequency under control conditions: 1.04 ± 0.15 Hz, n = 6 cells; frequency under high-AChE conditions: 0.32 ± 0.14 Hz, n = 8 cells. * P< 0.05, ** P< 0.001.
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with non-O-glycosylated β-neurexins was novel. Previ-
ous studies showed that AChE-S and AChE-R differ in
structure of C-terminals and have inverse effects on
amyloid fibrils formation [47,48], implying that the two
neuronal AChE variants may have distinctive roles in
AD pathology. Therefore, the significance of interactions
between the non-O-glycosylated β-neurexins and the two
AChE variants awaits further studies.
The AChE–β-neurexin interaction requires N-glycosyl-
ation of either AChE or neurexin-1β, because there was
no co-precipitation of neurexin-1β with AChE when
the N-glycosylases were inhibited (Figure 4C, lane 4).
In addition, co-precipitation of AChE and neurexin was
observed in the lysate of co-cultured cells that had been
transfected with either AChE-S or Nrxn-1β-1’ before
co-culturing (Figure 4E); in contrast, co-precipitation
was not observed in a mixture of lysates from cells that
were separately transfected with either AChE-S or Nrxn-
1β-1’ (not shown). These results indicate that AChE
monomers interact with the extracellular domain of β-
neurexins, specifically those located in the cell membrane.
The enzymatic residues of AChE locate at the bottom
of a “gorge” of the molecule [49]. The surface anionic
residues surrounding the gorge are critical for AChE
to interact with various proteins [35,36,50]. However,
it is unlikely that the interaction between AChE and
β-neurexins occurs via these surface anionic residues
because BW284c51, a selective AChE inhibitor that
specifically binds to the anionic residues [51] enhanced,rather than interrupted, co-immunoprecipitation of AChE
with neurexin-1β (Figure 1C). Like AChE, the ectodomain
of neuroligin-1 also possesses surface anionic residues.
Given that binding of the ectodomain of neuroligin-1 to
neurexin-1β occurs on the side opposite to the surface
anionic residues [52], we propose that AChE similarly
interacts with β-neurexins through a region on the op-
posite side of the surface anionic residues (see Figure 9).
Physostigmine, an AChE inhibitor that binds to enzymatic
residues in the gorge of AChE, also increased the inter-
action between neurexin-1β and AChE-S (Figures 4D
and E). This effect of physostigmine is not likely to be
due to its catalysis-inhibiting activity, because no innate
cholinergic signaling mechanism is known to exist in
HEK293 cells. Future structural studies will help to deter-
mine the molecular mechanisms by which these AChE
ligands regulate the interaction between AChE and
neurexin. The activity of AChE in the brain is critically
associated with neural development and cognition [53].
AChE expression peaks in the fetus during the neurito-
genic period before synaptogenesis [54] and gradually
declines upon postnatal maturation [55,56]. However,
in the adult brain, the expression of AChE increases in
response to psychological stressors [57-59]. This increased
AChE expression is detrimental to the synapses [43] and
ultimately to brain function [60]. In spite of this, know-
ledge of the molecular mechanism by which excess AChE
impairs the integrity of synapses has been lacking. The
observation that AChE interacts with non-O-glycosyl-
ated β-neurexin led us to test the hypothesis that excess
Figure 9 Possible interactions among neurexin (Nrxn), neuroligin (Nlgn) and acetylcholinesterase (AChE) at glutamatergic synapses
under normal and pathological conditions. Under normal conditions, O-glycosylated β-neurexins are primarily associated with neuroligin-1,
forming trans-synaptic junctions and inducing pre- and post-synaptic maturation. Under pathological conditions, N-glycosylated AChE increases
(or O-glycosylation of β-neurexins decreases), allowing more interactions between N-glycosylated AChE and non-O-glycosylated β-neurexins and
a consequent loss of glutamatergic synapses and intracellular accumulation of post-synaptic proteins such as postsynaptic density protein 95
(PSD-95) and the glutamate receptor subunits GluN1a (NR1a) and GluA2 (GluR2).
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at excitatory synapses. Indeed, adding AChE-S to the cul-
ture medium reduced the neurexin–neuroligin association
(Figure 5A). Notably, the reduction was small, which
may reflect the facts that AChE interacts only with a
small amount of non-O-glycosylated β-neurexin proteins
(see Figure 4A). Nevertheless, increasing extracellular
AChE did largely inhibit the neuroligin-induced de novo
formation of presynaptic structure (Figure 5B, bottom
row). Moreover, including both AChE and AChE inhibitor
in the culture medium significantly decreased glutamate-
evoked currents (Figure 6), reduced the number of gluta-
matergic synapses (Figure 7) and lowered the frequency
and amplitude of mEPSCs (Figure 8). Together, these re-
sults indicate that excess AChE could impair the integrity
of some native glutamatergic synapses.
Although the association between neurexin and neuroli-
gin is essential for both excitatory and inhibitory synapses
[61], neuroligin varies in terms of the isoforms present at
excitatory and inhibitory synapses. Specifically, neuroligin-
1 is primarily localized at glutamatergic synapses [18],
whereas neuroligin-2 is largely restricted to GABAergic
synapses [62]. In the present study, AChE exhibited
greater affinity for neurexin-1β-1’ (lacking the SS4 insert)
(Figure 4D). Given that neurexin-1β-1’ has a higher affin-
ity for neuroligin-1 and a lower affinity for neuroligin-2
[34], it is plausible that AChE preferentially disrupts the
interaction between neurexin-1β-1’ and neuroligin-1 at
glutamatergic synapses. Indeed, increased expression
of AChE reduces the cell surface clusters of glutamate
receptor subunits but increases the total proteins of
neuroligin, glutamate receptor subunits and postsynaptic
density protein 95 (PSD-95) in hippocampal neurons
[21], which together imply that excess AChE decreasesglutamatergic synapses and thus allows cellular accumula-
tion of postsynaptic proteins. Nevertheless, the issue as to
whether AChE does not disrupt the association between
neurexin-1β and neuroligin-2 but selectively interrupts
the association between neurexin-1β and neuroligin-1,
requires more detailed studies.
Bi-directional signaling by adhesion molecules in the
pre- and post-synaptic compartments determines the
appropriate differentiation of synaptic structures [63].
The interaction of neurexins and neuroligins mediates
signaling across the synapse and ultimately shapes the
properties of neural networks [64]. Previous studies have
demonstrated that glycosylation of neurexin-1β is required
for such interactions [62]. In the current study, the major-
ity of membrane-targeted β-neurexins were modified by
both O- and N-glycosylation, whereas a small number
of β-neurexins in the membrane were linked only with
N-glycans (Figure 3). Interestingly, AChE monomers
interacted only with the non-O-glycosylated β-neurexins
(Figures 3 and 4), and such interactions might fine-tune
synaptic stability (Figures 7 and 8), probably possibly
through modulation of the neurexin–neuroligin associ-
ation (Figure 5).
Another important outcome of this study was the finding
that the AChE-neurexin interaction requires AChE N-gly-
cosylation (Figure 4C, lane 4). Given that N-glycosylated
AChE is significantly increased in the cerebrospinal fluid of
patients with AD [12], and that the expression of AChE
is negatively regulated by miR-132 [65], which largely
decreases in late-onset AD patients [66], it is plausible
that the interaction between AChE and neurexin increases
in the brains of AD patients, leading to damage at the
glutamatergic synapses. We propose that under normal
physiological conditions, a low concentration of N-glyco-
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has little effect on the synaptic stability (Figure 9).
However, under pathological conditions such as AD,
the quantity of N-glycosylated AChE monomers in the
brain increases greatly, to the point where the mono-
mers interact with β-neurexins, adversely affecting the
structure and function of a subset of glutamatergic
synapses. Such action of excessive AChE may also link
to other cognitive diseases, for example autism, because
alterations in cholinergic activity [67] and/or in neuroli-
gin-neurexin association [64] in the brain lead to autism
spectrum disorders.Conclusion
In summary, our studies demonstrated that excess gly-
cosylated AChE could interact with non-O-glycosylated
neurexin-1β, thus competitively disrupting a subset of the
neurexin–neuroligin junctions and consequently impairing
the integrity of some glutamatergic synapses. Our findings
may provide a molecular mechanism of excessive AChE
induced neurodegeneration.Methods
Complementary DNA construction
Complementary DNA (cDNA) encoding full-length human
AChE-S (hAChE-S), inactive hAChE-S (hAChE-Sin) and
human AChE-R (hAChE-R) [68] cloned into the pL5CA
expression vector were gifts from Dr. Hermona Soreq
at the Hebrew University of Jerusalem. cDNA encoding
a full-length rat neuroligin-1 [69] cloned in the pCMV5
expression vector (pCMVNL1), cDNA encoding a rat
neurexin-1β lacking alternatively spliced sequence 4
(SS4) (neurexin-1β-1’) from pCMVN1β-1 and cDNA
encoding a full-length rat neurexin-1β containing SS4
(neurexin-1β-3’) from pCMVN1β-3 [70] were gifts from
Dr. Thomas C. Südhof at Stanford University. To obtain
better immunobiochemical signals for neurexins, the
neurexin cDNA samples were inserted into a pcDNA3
expression vector tagged with 6-His [71,72]. Briefly, the
cDNA for full-length neurexin-1β-1’ and neurexin-1β-
3’ was amplified by polymerase chain reaction using
platinum Pfx DNA polymerase (Invitrogen, Carlsbad, CA)
from pCMVN1ß-1 and pCMVN1ß-3 cDNA, respectively.
The product of the polymerase chain reaction was
inserted into the BamHI-XbaI site of the pcDNA3,
positioned in frame upstream to the 6-His epitope and
followed by a stop codon. All constructs were re-se-
quenced, with confirmation of the absence of nucleotide
errors and the in-frame context of the neurexin cDNA
with 6-His. cDNA encoding His-tagged rat neurexin-
1β from those vectors was named neurexin-1β-1’-His
(Nrxn-1β-1’-His) and neurexin-1β-3’-His (Nrxn-1β-3’-His),
respectively.AChE-conditioned media
Human embryonic kidney 293 (HEK293) cells were main-
tained in Dulbecco’s modified Eagle medium (DMEM)
supplemented with 10% fetal calf serum in a 37°C humidi-
fied atmosphere containing 5% CO2. Cells at 75% conflu-
ence were transiently transfected with cDNA encoding
hAChE-S, hAChE-Sin or hAChE-R or with the expression
vector alone, using Lipofectamine 2000 transfection
reagent (Invitrogen), according to the manufacturer’s
instructions. Twelve hours after transfection, the DMEM
was replaced with fresh B27-supplemented Neurobasal
medium (1:50, Invitrogen). Twenty-four hours later, the
hAChE-conditioned media and the hAChE-free condi-
tioned medium (from cells transfected with expression
vector alone) were collected. Previous work has shown
that recombinant hAChE is secreted from transiently
transfected HEK293 cells as a soluble globular enzyme
[73]. The presence of active hAChE in the conditioned
medium was confirmed by an AChE activity assay accord-
ing to Ellman’s method, as previously described [21]. The
presence of catalytically inactive hAChE-S (hAChE-Sin) in
its conditioned medium was confirmed by immunoblot
assays.
Culture of Hippocampal neurons
Neuronal cell dissociation and culture were performed
as previously described [21,74]. Briefly, hippocampal cells
from Wistar rat embryos at day 18 (E18) were isolated by
mechanical trituration. The dissociated cells were cultured
on dishes or coverslips coated with poly-D-lysine (Sigma,
Oakville, Canada) at a density of 3 × 10 [4] cells/cm2 in
standard plating medium containing B27-supplemented
Neurobasal medium, 0.5 mML-glutamine, 25 μM glu-
tamic acid, 0.5 mM sodium pyruvate and 0.5% fetal bovine
serum. The hippocampal cells were incubated for 18 hours
at 37°C in an atmosphere containing 5% CO2, after which
the plating medium was replaced with culture medium
containing B27-supplemented Neurobasal medium and
L-glutamine (0.5 mM). This culture medium supports
neuronal growth while restricting the growth of other
cell types [75]. According to the requirements of specific
experiments, the neurons were treated and used at various
days in vitro (DIV).
To investigate whether an increase in AChE expression
affects neuronal function, two sets of cultured hippo-
campal neurons at the fifth DIV were transfected (using
Lipofectamine 2000 transfection agent) with cDNA, one
set with cDNA encoding hAChE-S and the other set with
cDNA encoding hAChE-R, along with a green fluorescent
protein (GFP)-encoding vector. Neurons transfected with
both the pL5CA expression vector and the GFP-encoding
vector were used as controls. Three hours after transfec-
tion, the transfection medium was replaced with fresh
B27-supplemented Neurobasal medium. To eliminate the
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physostigmine (10 μM, Sigma) or 1, 5-bis (4-allyldimethy-
lammoniumphenyl)-pentan-3-one dibromide (BW284c51,
5 μM, Sigma) was added to the media. Twelve to fourteen
hours after transfection, a fluorescence microscope was
used to identify the transfected neurons (labeled with GFP
fluorescence), and the transfection rate was calculated.
To study whether excess AChE impairs neuronal function
by an extracellular mechanism, other sets of cultured
hippocampal neurons at the fifth DIV were treated with
AChE-conditioned media or medium to which purified
hAChE-S had been added (Sigma, C-1682; generated
from the same hAChE cDNA used in this study) in the
presence of physostigmine (10 μM).
Immunocytochemical assays in cultured neurons
Immunocytochemical assays were performed as previously
described [21,74], with minor modifications. Briefly, live
cultured hippocampal neurons at the 11th DIV, with or
without BW284c51 treatment (5 μM, for 3 days), were in-
cubated with anti-AChE antibody (Chemicon, Temecula,
CA, diluted 1:100 in the medium) for 2 hours. After wash-
ing with phosphate-buffered saline (PBS), the neuronal
cells were fixed with 3.7% paraformaldehyde and 4%
sucrose in PBS for 10 minutes. Following incubation
with a Cy3-conjugated donkey anti-mouse secondary
antibody (Jackson ImmunoResearch Laboratories, West
Grove, PA), the cells were permeabilized with 0.1% Triton
X-100 for 10 minutes, blocked in 5% normal donkey
serum for 1 hour and then incubated with anti-neurexin
antibody (Santa Cruz Biotechnology, Santa Cruz, CA,
1:100) at 4°C overnight. Following three gentle washes,
cells were incubated with fluorescein isothiocyanate-
conjugated donkey anti-goat secondary antibody (Jackson
ImmunoResearch Laboratories) for 1 hour. For immuno-
cytochemical assays of the glutamate receptor subunit
GluR2 (GluA2) and the presynaptic vesicular protein
synapsin, cultured neurons at the ninth DIV were treated
with AChE-conditioned medium or with AChE-free con-
ditioned medium in the presence of 10 μM physostigmine.
At the 12th DIV, the treated neurons were fixed with 3.7%
paraformaldehyde and 4% sucrose in PBS for 15 minutes
and were then permeabilized in 0.1% Triton X-100 for
10–15 minutes. Following 1 hour of blocking with 5%
goat serum, the cells were incubated with anti-GluR2
or anti-synapsin (Chemicon, 1:1000).
Confocal microscopy
Visual fields under a confocal microscope (Carl Zeiss,
Gottingen, Germany) were randomly selected by blindly
moving the cell-culture coverslip. Dual immunofluores-
cence was captured in two-channel mode, as previously
described [76]. Digital images were obtained with a 63×
objective lens. Multiple electronic images of cells wereobtained and saved in a computer for analysis. For both
control and treated neurons, the number of immuno-
fluorescent protein particles was counted and the length
of neurites was measured using Image J software (NIH
Image, NIH, Bethesda, MD). This information was used to
calculate the density of immunoreactive protein clusters,
expressed as number of clusters per 20 μm length of
dendrite. For colocalization analysis, confocal microscopic
images of the two channels were background-subtracted
and the threshold of fluorescent punctate structures at
neuronal dendrites was set to the level at least twofold
greater than the background. As previously described [77],
colocalization was measured by means of Image J as the
fraction of the image filed labeled for one channel that
was also labeled for the second channel.
Co-immunoprecipitation of neurexin and AChE from
cultured neurons
At the seventh DIV, the cultured hippocampal neurons,
with or without BW284c51 treatment (5 μM, for 3 days),
were lysed in a buffer containing 20 mM Tris–HCl
(pH 7.5), 150 mM NaCl, 0.5% Triton X-100 and protease
inhibitors. Cell lysate (500–1000 μl, concentration 1 μg/μl)
was incubated with Protein A-Sepharose beads (Sigma)
at 4°C for 30 minutes to remove nonspecific binding
proteins. The cleared lysate was then incubated with anti-
neurexin antibody (Santa Cruz Biotechnology) or anti-
AChE antibody (BD Biosciences, Franklin Lakes, NJ)
overnight at 4°C, to allow reciprocal co-immunoprecipita-
tion of neurexin and AChE. For controls, cell lysate was
incubated with the same amount of normal IgG (Santa
Cruz Biotechnology) or without added antibody. After
incubation with Protein A-Sepharose beads for 2 hours,
the immunoprecipitates were washed three times with
ice-cold lysis buffers, and the binding proteins were
eluted with sample buffer. The AChE inhibitor BW284c51
(5 μM) was included in all buffers used for immunopre-
cipitation. The general procedures for Western blotting
were the same as previously described [21]. Briefly, after
electro-transfer of the precipitates to nitrocellulose mem-
brane (Bio-Rad, Hercules, CA), AChE or neurexin in
the immunoprecipitated material was probed by immuno-
blotting with anti-AChE antibody (BD Biosciences) or
anti-neurexin antibody (Santa Cruz Biotechnology).
Transfection of HEK293 cells with neurexin-1β and
hAChE cDNA
To study whether specific AChE isoforms interact with
neurexin-1β, HEK293 cells were transiently transfected
with plasmid DNA encoding neurexin-1β and specific
isoforms of hAChE, using Lipofectamine 2000 transfection
agent according to the manufacturer’s protocol. Briefly,
HEK293 cells at 70%–80% confluence were co-transfected
with cDNA encoding Nrxn-1β-1’-His and either hAChE-S
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Nrxn-1β-1’-His, hAChE-S or hAChE-S-R cDNA alone.
To study whether AChE interacts extracellularly with
Nrxn-1β-1’-His on the cell membrane, one set of HEK293
cells was transfected with hAChE-S and another set with
Nrxn-1β-1’-His. Five hours later, the HEK293 cells trans-
fected with Nrxn-1β-1’-His were gently stripped off and
then re-seeded onto the HEK293 cells transfected with
hAChE-S (or onto cells transfected with control vector), at
a ratio of 1:1.5. For all transfection operations, equal
amounts of transfected DNA were obtained by adding
vector DNA, and the catalytic action of AChE was blocked
by adding physostigmine (10 μM) to the medium.
Characterization of transfected proteins in HEK293 cells
To detect AChE variants, HEK293 cells were lysed in a
buffer containing 20 mM Tris–HCl (pH 7.5), 150 mM
NaCl, 1% Triton X-100 and proteinase inhibitors. Immuno-
blotting of the cell lysate or the culture medium collected
from the transfected cells was performed under non-
reducing conditions. Specifically, the protein sample was
applied to 10% gel using the loading buffer without the
reducing agent, as described previously [78].
To study the glycosylation profiles of proteins expressed
in HEK293 cells, protein samples obtained from the lysates
of transfected cells or from the culture medium were
denatured and incubated with peptide N-glycosidase F
(PNGase F), O-glycosidase and /or sialidase using Enzym-
atic CarboRelease Kit (QA-Bio, Palm Desert, CA) for
3 hours at 37°C according to the manufacturer’s protocol
and then processed for Western blotting. To study the ef-
fect of N-linked glycosylation on the interaction between
AChE and β-neurexins, the transfected cells were treated
(5 hours after transfection) with tunicamycin (0.5 μg/ml,
Sigma), a selective inhibitor of N-glycosylase, or the equi-
valent volume of dimethyl sulfoxide (vehicle control).
Cells were lysed 40–48 hours after transfection, and co-
immunoprecipitation was performed as described above.
Membrane surface proteins in transfected HEK293 cells
were examined by surface biotination of intact cells with
EZ-Link Sulfo-NHS-SS-Biotin reagent (Pierce Biotechnol-
ogy, Rockford, IL) according to the manufacturer’s proto-
col. Briefly, intact cells were washed and then incubated in
the reagent (0.5 mg/ml in PBS, pH 8.0) for 1 hour on ice.
Unbound biotin was quenched by incubation in 50 mM
Tris, pH 8.0, for 10 minutes on ice. Cells were washed two
times with ice-cold PBS and then lysed. The biotinylated
proteins were precipitated by rocking with streptavidin
beads (Pierce) overnight at 4°C. The beads were washed
three times in lysis buffer, and bound proteins were eluted
in sodium dodecyl sulfate sample buffer. The membrane
proteins were confirmed by immunoblotting with specific
antibodies.Co-immunoprecipitation of protein samples from
transfected HEK293 cells
Transfected HEK293 cells were used for co-immunopre-
cipitation assays 40–48 hours after transfection. Briefly,
the transfected cells were lysed in ice-cold 1% Triton X-
100 and 0.5% sodium deoxycholate in PBS supplemented
with protease inhibitors. AChE and neurexin were co-
immunoprecipitated by incubating the cleared lysates
with anti-AChE antibody (Santa Cruz Biotechnology)
or anti-His antibody (QIAGEN, Hilden, Germany) for
3 hours at 4°C. Physostigmine (10 μM) was included in
all buffers used for immunoprecipitation. Neurexin or
AChE in the immunoprecipitated material was probed
by immunoblotting with anti-His followed by anti-mouse
light-chain-specific secondary antibody (Jackson Immu-
noResearch Laboratories) or with AChE antibody (Santa
Cruz Biotechnology). To control for efficiency of transfec-
tion, the expression levels of all proteins were assessed by
Western blotting. The blot films were scanned with a
GS800 densitometer (Bio-Rad).
To investigate whether increased extracellular AChE
interrupts the neurexin–neuroligin association, HEK293
cells were co-transfected with cDNA encoding Nrxn-1β-
1’-His and neuroligin-1, and the transfected HEK293
cells were cultured in AChE-S-conditioned medium or
AChE-free conditioned medium. Twenty-four hours after
co-transfection, HEK293 cells were lysed as previously
described [17], with minor modification, in a buffer con-
taining (in mM) 20 Tris–HCl (pH 7.5), 100 NaCl, 4 KCl
and 5 CaCl2, as well as 2% CHAPS cell lysis buffer and
protease inhibitors, at 4°C. The cell lysate was cleared
as described above and then incubated with anti-His
antibody (QIAGEN), and the precipitated neuroligin
was confirmed by immunoblotting with anti-neuroligin
antibody (Synaptic Systems, Göttingen, Germany).
Co-culture of neurons with neuroligin-expressing
HEK293 cells
HEK293 cells plated at low density on poly-D-lysine
coated glass coverslips were cultured in DMEM. Five
hours after plating, the medium was replaced with neuron
plating medium, and dissociated E18 hippocampal cells
(3 × 10 [4] cells/cm [2]) were plated onto the HEK293
cells. On the fifth day of co-culture, the cells were trans-
fected with rat neuroligin-1 cDNA and the GFP-encoding
vector, using Lipofectamine 2000 transfection agent. Five
hours after transfection, the medium was replaced with
AChE-conditioned medium or AChE-free conditioned
medium in the presence of 10 μM physostigmine. Two
days after transfection of neuroligin-1, the cells were
processed according to the procedures used for neu-
rons (see above) and then incubated with anti-synapsin
(Chemicon, 1:1000) at 4°C overnight. Following incubation
with Cy3-conjugated secondary antibodies at 4°C for
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confocal microscopic examination.
Patch-clamp recordings in cultured neurons
Control and treated neurons were used for patch-clamp
recordings 40–48 hours after treatment. Transfected neu-
rons were identified by green fluorescence, and a sample
of these neurons was randomly selected for recordings.
The procedures for voltage-clamp recording were as pre-
viously described [21]. Briefly, recordings were obtained
by means of an Axopatch-1D amplifier (Axon Instruments,
Foster City, CA) with holding potential of −60 mV. The
extracellular solution contained (in mM): 145 NaCl, 1.3
CaCl2, 5.4 KCl, 25 HEPES and 28 glucose, with pH 7.4 and
osmolarity about 315 mOsm. The patch electrodes, made
with thin-walled glass tubes, were filled with a solution
containing (in mM) 150 KCl, 10 HEPES, 1 CaCl2, 2
MgCl2, 2 tetraethylammonium and 4 ATP, with pH 7.35
and osmolarity 310 mOsm. To study the effects of AChE
on the function of the major transmitter receptors
in neurons, glutamate-evoked and γ-aminobutyric acid
(GABA)-evoked currents were studied. Rapid application
of the receptor agonist was achieved with a computer-
controlled, multibarrel-perfusion system (SF-77B, Warner
Instruments, Hamden, CT). Electrical signals were digi-
tized, filtered (1–2 kHz) and acquired on-line by means of
the data acquisition and analysis software Clampex (Axon
Instruments). The peak amplitude of evoked currents
was measured off-line using Clampfit software (Axon
Instruments). For recording of miniature excitatory post-
synaptic currents (mEPSCs), 0.5 μM of tetrodotoxin and
20 μM of bicuculline methiodide were included in the
ECS. All recordings were performed at room temperature
(22-24°C). In each recording, at least 120- mEPSC events
were collected for analysis. The amplitude and frequency
of mEPSCs were analyzed using the program Mini-analysis
(Synaptosoft Inc., Decatur, GA).
Statistical analysis
Statistical analyses were performed using Student’s un-
paired or paired t tests as appropriate. Data are expressed
as mean ± standard error of the mean (SEM). A p value <
0.05 was considered significant.
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